Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

ClinicalTrials.gov ID: NCT04269200

Public ClinicalTrials.gov record NCT04269200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Study identification

NCT ID
NCT04269200
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
805 participants

Conditions and interventions

Interventions

  • olaparib Drug
  • durvalumab Biological
  • durvalumab placebo Drug
  • olaparib placebo Drug
  • Carboplatin Drug
  • Paclitaxel Drug

Drug · Biological

Eligibility (public fields only)

Age range
18 Years to 150 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 4, 2020
Primary completion
Jul 7, 2024
Completion
Mar 31, 2027
Last update posted
May 31, 2026

2020 – 2027

United States locations

U.S. sites
50
U.S. states
29
U.S. cities
48
Facility City State ZIP Site status
Research Site Tucson Arizona 85719
Research Site Concord California 94520-2278
Research Site La Jolla California 92093
Research Site San Francisco California 94158
Research Site Santa Barbara California 93105
Research Site Aurora Colorado 80012
Research Site Fort Lauderdale Florida 33316
Research Site Tampa Florida 33612
Research Site Savannah Georgia 31404
Research Site Honolulu Hawaii 96826
Research Site Arlington Heights Illinois 60005
Research Site Chicago Illinois 60637
Research Site Indianapolis Indiana 46237
Research Site Louisville Kentucky 40207
Research Site Baton Rouge Louisiana 70817
Research Site Boston Massachusetts 02111
Research Site Saint Paul Minnesota 55125
Research Site Jackson Mississippi 39216
Research Site Lebanon New Hampshire 03756
Research Site Camden New Jersey 08103
Research Site Paramus New Jersey 07652
Research Site New York New York 10011
Research Site New York New York 10029
Research Site Pinehurst North Carolina 28374
Research Site Cleveland Ohio 44109
Research Site Cleveland Ohio 44124
Research Site Dayton Ohio 45459
Research Site Oklahoma City Oklahoma 73104
Research Site Tulsa Oklahoma 74134
Research Site Eugene Oregon 97401
Research Site Tigard Oregon 97223
Research Site Pittsburgh Pennsylvania 15224
Research Site Providence Rhode Island 02905
Research Site Sioux Falls South Dakota 57105
Research Site Chattanooga Tennessee 37403
Research Site Germantown Tennessee 38138
Research Site Knoxville Tennessee 37920
Research Site Bedford Texas 76022
Research Site Dallas Texas 75231
Research Site Houston Texas 77030
Research Site San Antonio Texas 78240
Research Site Sugar Land Texas 77479
Research Site Tyler Texas 75702
Research Site Webster Texas 77598
Research Site Fairfax Virginia 22031
Research Site Norfolk Virginia 23502
Research Site Seattle Washington 98195
Research Site Morgantown West Virginia 26505
Research Site Madison Wisconsin 53792
Research Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04269200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 31, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04269200 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →